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Contribution of syndecans to 
cellular internalization and 
fibrillation of amyloid-β(1–42)
Tamás Letoha  1, Anett Hudák1, erzsébet Kusz1, Aladár Pettkó-Szandtner2, 
Ildikó Domonkos2, Katalin Jósvay2, Martin Hofmann-Apitius  3 & László Szilák4
Intraneuronal accumulation of amyloid-β(1–42) (Aβ1–42) is one of the earliest signs of Alzheimer’s 
disease (AD). Cell surface heparan sulfate proteoglycans (HSPGs) have profound influence on the 
cellular uptake of Aβ1–42 by mediating its attachment and subsequent internalization into the cells. 
Colocalization of amyloid plaques with members of the syndecan family of HSPGs, along with the 
increased expression of syndecan-3 and -4 have already been reported in postmortem AD brains. 
Considering the growing evidence on the involvement of syndecans in the pathogenesis of AD, we 
analyzed the contribution of syndecans to cellular uptake and fibrillation of Aβ1–42. Among syndecans, 
the neuron specific syndecan-3 isoform increased cellular uptake of Aβ1–42 the most. Kinetics of 
Aβ1–42 uptake also proved to be fairly different among SDC family members: syndecan-3 increased 
Aβ1–42 uptake from the earliest time points, while other syndecans facilitated Aβ1–42 internalization 
at a slower pace. Internalized Aβ1–42 colocalized with syndecans and flotillins, highlighting the role 
of lipid-rafts in syndecan-mediated uptake. Syndecan-3 and 4 also triggered fibrillation of Aβ1–42, 
further emphasizing the pathophysiological relevance of syndecans in plaque formation. Overall our 
data highlight syndecans, especially the neuron-specific syndecan-3 isoform, as important players in 
amyloid pathology and show that syndecans, regardless of cell type, facilitate key molecular events in 
neurodegeneration.
Dementia is one of the most important health-care problems in ageing populations1,2. The most frequent cause 
of dementia is Alzheimer’s disease (AD)3,4. Induced by widespread neurodegeneration, AD is a rapidly growing 
epidemic affecting about 30 million individuals worldwide5. Beginning with insidious deterioration of higher 
cognition that progresses to severe dementia, currently untreatable AD represents a major unmet medical need6,7.
There is compelling evidence that amyloid beta peptide (Aβ), rendered in β-sheet dominated senile plaques, 
is a hallmark of AD8. Although the precise role of Aβ in AD is not fully understood, plaque formation of accu-
mulated Aβ is still considered to be a central event in disease development9,10. The accumulation of Aβ arises 
from the imbalance between its production and clearance11. Recent evidence in humans suggest that faulty Aβ 
clearance has a profound influence in the pathogenesis of AD12. Cellular studies shows that neuronal endocytic 
and lysosomal systems become damaged early in AD, leading to the intraneuronal build-up of Aβ that precedes 
extracellular plaque formation13–19. Intracellular accumulations of the aggregation-prone Aβ1–42 isoform then 
promotes cell-to-cell transfer, also an early cellular event that is seemingly independent of later appearances of 
cellular toxicity20. Thus, cellular uptake of Aβ1–42 has profound influence on the course of AD.
Interaction of heparan sulfate proteoglycans (HSPGs) with Aβ has been well documented21–25. HSPGs have 
been implicated in several pathogenic features of AD, including its colocalization with amyloid plaques26–29. 
Binding of Aβ1–42 to HSPGs is mediated by electrostatic interactions arising between the negatively charged 
heparan sulfate (HS) chains and the cationic heparin-binding motif of Aβ1–4230,31. Attachment of Aβ1–42 to 
HS chains induces its multimerization, leading to the formation of toxic fibrillar aggregates32–34. Fibrillation of 
Aβ1–42 meanwhile increases its interactions with HSPGs, such as syndecan-4 (SDC4), the universally expressed 
isoform of the syndecan (SDC) family of transmembrane proteoglycans35. Besides SDC4, number of other 
HSPGs, including SDC3, the neuron specific isoform of the SDC family, are significantly increased in human AD 
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brains and through modulating Aβ aggregation and clearance they promote amyloid pathology11. In other stud-
ies, SDC1-3 were also found to be associated with the majority of senile plaques in AD brains36.
Due to their highly sulfated polyanionic glycosaminoglycan (GAG) chains, SDCs interact with myriad of 
extracellular cationic ligands and transmit signals from the extracellular space towards the cellular interior, 
hence influencing cellular metabolism, transport and information transfer37–39. As key regulators of cell signal-
ing and biological functions, SDCs also play important roles in the pathogenesis of several human diseases40–42. 
Expression of SDCs follow a tissue specific pattern: SDC1 is widely expressed in epithelial and plasma cells, 
SDC2 in mesenchymal cells, whereas SDC3 is mainly localized to neural tissues. In contrast to other SDCs, SDC4 
is abundant in many cell types38,43. SDCs share similar structure: a conserved short, one span transmembrane 
domain (TM) and the approximately 30 amino acid length cytoplasmic domain (CD). Through their CDs, SDCs 
effect a large number of signaling cascades44. The N-terminal extracellular domains (ectodomains) of SDCs con-
tain three GAG attachment sites for HS near the N terminus and may bear chondroitin sulfate (CS) at the jux-
tamembrane region45. The SDC4 ectodomain also compromises a cell-binding domain (CBD) mediating cell to 
cell attachment46. SDCs also mediate cellular uptake of a wide variety of macromolecules, along with viruses and 
bacteria47–50. During endocytosis, ligand- or antibody-mediated clustering induces the redistribution of SDCs 
to lipid rafts and stimulation of a lipid raft-dependent, but clathrin- and caveolae-independent endocytosis of 
the SDC-ligand complex51. Contrary to SDCs, the cell surface HSPG glypicans mediate internalization of their 
ligands primarily through caveolin-dependent endocytosis52.
Due to their involvement in endocytosis, SDCs are attractive targets to deliver macromolecules into the cells53–55. 
Throughout the years, our research group has been exploring the SDC-mediated uptake of cell-penetrating pep-
tides (CPPs), small cationic peptides enabling the efficient intracellular delivery of membrane-impermeable bio-
molecules56–59. Cationic CPPs such as Tat, penetratin or polyarginine all utilize SDC-dependent macropinocytic 
pathways to enter the cells. Since CPPs internalized via SDC-mediated routes can bypass lysosomal degradation, 
aiding CPP-attached cargoes to exert their bioactivity intracellularly, SDC-mediated uptake and intracellular 
accumulation of fibrillar Aβ1–42 aggregates could have indeed damaging effects on neurons. The different expres-
sion pattern of SDCs in the CNS also makes SDCs exciting molecular targets to be explored in the course of 
neurodegeneration60.
Considering the evidence on the potential involvement of SDCs in membrane attachment and subsequent 
cellular delivery of Aβ1–42, we decided to analyze the internalization of Aβ1–42 in cellular models express-
ing distinct SDC isoforms. In order to analyze SDCs’ effect of without the interference of other HSPGs or 
caveolae-mediated endocytosis, we chose the K562 cell line – a human myelogenous leukemia cell line with 
reportedly no expression of any members of the syndecan or glypican HSPG families, along with no caveo-
lae expression – as model cells to express the various SDC isoforms61–64. Quantitative uptake assays with SDC 
transfectants enabled quantitative assessment of SDCs’ contribution to Aβ1–42 uptake, while studies with SDC 
structural mutants revealed the role of SDC domains in interaction with the peptide. Utilization of Thioflavin T 
(ThT) fluorescence assays and scanning electron microscopy also helped to assess the effect of SDCs on Aβ1–42 
fibrillation, the molecular mechanism responsible for the formation of toxic amyloid oligomers. Observations 
obtained on stable SDC transfectants (established in K562 cells) were also confirmed in SH-SY5Y neuronal cells.
Overall our data highlight SDCs, especially the neuron-specific SDC3 isoform, as important players in 
the amyloid pathology of AD and show that SDCs, regardless of cell type, facilitate key molecular events in 
neurodegeneration.
Results
Contribution of sDCs to Aβ1–42 uptake and fibrillation. While cell surface HSPGs have been already 
identified as key targets for the cellular attachment and internalization of Aβ1–42, the exact contribution of trans-
membrane SDCs to Aβ1–42 endocytosis has not been assessed yet. To enable the exact assessment of SDCs’ 
contribution to cellular uptake of Aβ1–42, while minimizing the interfering effects of other HSPGs or caveo-
lae-mediated endocytosis, stable transfectants of SDCs were created in the K562 cells, a cell line with reportedly 
low HSPG and no syndecan or glypican expression, along with no detectable levels of caveolin-1, the main com-
ponent of caveolae61–65. The low expression of membrane HSPGs (see Supplementary Fig. S1. for comparison of 
HS expression of K562 cells to that of SH-SY5Y, a widely used neuronal cell line) and the inability to form cave-
olae, the source of caveolar endocytosis, makes K562 an ideal human model cell line to study the effect of SDC 
overexpression on Aβ1–42 uptake without the interference of other HSPGs or caveolae-mediated endocytosis. 
As the role of HS in the cellular attachment of Aβ1–42 has been already demonstrated, SDC transfectants were 
standardized according to their HS expression (Supplementary Fig. S2). (It is worth noting that contrary to HS, 
we could not detect any CS expression on wild-type K562 cells and SDC transfectants [Supplementary Fig. S3]). 
Thus SDC transfectants with similar level of HS expression were selected and, along with wild-type (WT) K562 
cells, treated with FITC-labeled Aβ1–42 or transferrin (Trf), the marker of clathrin-mediated endocytosis, for 
1, 3, 6 and 18 hours. Contribution of SDCs to cellular uptake and binding of FITC-Aβ1–42 or FITC-Trf was 
then quantified with quantitative flow cytofluorometric assays. Protein internalization was assessed by adding 
trypan blue (dissolved at a concentration of 0.25% in ice-cold 0.1 M citrate buffer) 1 min before the analyses, thus 
extracellular fluorescence of surface bound fluorescent proteins (Aβ1–42 or Trf) was quenched66. Extracellularly 
attached proteins were quantified by the difference of the fluorescence measures of protein-treated samples 
unquenched and quenched with trypan blue. As Fig. 1. shows, internalization of Aβ1–42 was highest in SDC3 
transfectants at every time points. SDC4 transfectants surpassed WT K562 cells in uptake of Aβ1–42 after 6 h of 
incubation, while SDC2 bested K562 cells in uptake and attachment of Aβ1–42 only at 18 h. Compared to K562 
cells, cellular uptake of Aβ1–42 into SDC1 transfectants were lower until 18 h of incubation. On the other hand, 
uptake of Trf, the marker of clathrin-mediated endocytosis, was higher in K562 cells than in SDC1, 2 and 3 
transfectants, while SDC4 exhibited slightly higher Trf uptake levels than WT K562 cells. Attachment of Aβ1–42 
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was highest in SDC3 transfectants and peaked at 6 h of incubation. Extracellular attachment of Aβ1–42 in SDC4 
transfectants was also higher compared to WT K562 cells, while both SDC1 and SDC2 exhibited similar extracel-
lularly attached Aβ1–42 levels as WT K562 cells. In case of Trf, attachment of all cells were quite similar, except 
for SDC1 that seemed to bind less Trf.
After assessing uptake kinetics of Aβ1–42, we moved on to study the fibrillation of the peptide. It is widely 
established, that polyanions, like heparin and HS facilitates the fibrillation of Aβ1–4234,67,68. After demonstrating 
SDCs’ contribution to Aβ1–42 uptake, we also analyzed SDCs’ effect on Aβ1–42 fibrillation. ThT fluorescence 
studies quantitatively showed that SDCs, especially SDC3 and SDC4 significantly (p < 0.05) facilitate the fibril-
lation of Aβ1–42 (Fig. 2a). Compared to WT K562 cells with relatively low surface HS expression, SDC3 and 
SDC4 induce the fibrillation of Aβ1–42 even after 1 h of incubation, as shown by increased ThT fluorescence of 
Aβ1–42-treated SDC3 and 4 transfectants. Simultaneous scanning electron microscopy studies also confirmed 
the fibrillation triggering effect of SDCs - especially SDC3 and SDC4 - on surface attached Aβ1–42 (Fig. 2b). Thus 
Figure 1. Kinetics of Aβ1–42 and Trf uptake. WT K562 cells and SDC transfectants were incubated with 
FITC-labeled Aβ1–42 or Trf for 1, 3, 6 and 18 h at 37 °C. Cellular uptake and attachment was analyzed with flow 
cytometry. (a,b) Flow cytometry histograms showing kinetics of intracellular fluorescence following incubation 
with fluorescent Aβ1–42 and Trf, respectively. (c–f) Detected intra- and extracellular fluorescence intensities 
of Aβ1–42 or Trf-treated cells were normalized to those of WT K562 cells treated with the respective proteins 
(either Aβ1–42 or Trf) for 1 h. The lines represent mean ± SEM of four independent experiments.
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scanning electron microscopy also showed increased number of fibrillar Aβ1–42 assemblies on SDC3 and SDC4 
overexpressing cells, even after 1 h incubation. Confocal microscopy studies then revealed ThT labeled fibrillar 
structures inside of Aβ1–42 treated cells, especially in SDC3 and SDC4 transfectants, suggesting while triggering 
Aβ1–42 fibrillation, SDCs also mediate the intracellular translocation of Aβ1–42 oligomers (Fig. 2c).
Considering the results of the initial uptake kinetics and fibrillation studies, we moved on to analyze the 
cellular internalization of Aβ1–42 at 18 h of incubation, when differences in Aβ1–42 uptake and fibrillation was 
the greatest between SDC transfectants and WT K562 cells. Compared to WT K562 cells, all SDC transfectants 
exhibited higher uptake of Aβ1–42 at 18 h (p < 0.01). Among SDC transfectants, the neuron specific SDC3 inter-
nalized Aβ1–42 the most and Trf the least (Fig. 3a–d). Thus the previously observed difference in Aβ1–42 and Trf 
uptake (along with cellular attachment) became indeed obvious: while SDC1, 2 and 3 all increased internalization 
of Aβ1–42, cellular uptake of Trf, the marker of clathrin-mediated endocytosis were reduced in all these SDC 
Figure 2. Effects of SDCs on Aβ1–42 fibrillation. WT K562 cells and SDC transfectants were incubated with 
Aβ1–42 at a concentration of 5 μM for 1 h to 18 h at 37 °C. (a) After 1, 3, 6 and 18 h of incubation, the cells were 
treated with ThT at a concentration of 15 μM for 10 mins and fluorescence was measured. Amyloid fluorescence 
is expressed as fold change over background ThT fluorescence. The bars represent mean ± SEM of four 
independent experiments. Statistical significance vs Aβ1–42-treated WT K562 cells was assessed by analysis of 
variance (ANOVA). *p < 0.05 vs Aβ1–42-treated WT K562 cells; **p < 0.01 vs Aβ1–42-treated WT K562 cells. 
(b) Scanning electron microscope visualization of WT K562 cells and SDC transfectants treated with Aβ1–42 
at a concentration of 5 μM for 1, 6 or 18 h. Representative images of three independent experiments are shown. 
Scale bar = 1 μm. (c) CLSM visualization of ThT labeled, intracellular Aβ1–42 fibrils in WT K562 cells and SDC 
transfectants. Representative images of three independent experiments are shown. Scale bar = 5 μm.
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transfectants (p < 0.01), suggesting that in case of SDC1, 2 and 3 transfectants, the internalization of Aβ1–42 and 
Trf occur through different routes. Compared to WT K562 cells, extracellular attachment of Aβ1–42 was also 
increased on SDC3 and 4 transfectants (p < 0.05 and p < 0.01, respectively), while in case of Trf, extracellular 
Figure 3. Cellular uptake of Aβ1–42 and Trf into WT K562 cells and SDC transfectants. WT K562 cells and 
SDC transfectants were incubated with FITC-labeled Aβ1–42 or Trf for 18 h at 37 °C. Cellular uptake of Aβ1–42 
was then analyzed with flow cytometry and confocal microscopy. (a,b) Flow cytometry histograms showing 
intracellular fluorescence WT K562 cells and SDC transfectants, following 18 h incubation with Aβ1–42 and 
Trf, respectively. (c,d) Detected cellular fluorescence intensities were normalized to FITC-Aβ1–42 or FITC-
Trf-treated WT K562 cells as standards. The bars represent mean ± SEM of nine independent experiments. 
Statistical significance vs standards (FITC-Aβ1–42 or FITC-Trf-treated WT K562 cells) was assessed by analysis 
of variance (ANOVA). *p < 0.05 vs standards; **p < 0.01 vs standards; ***p < 0.001 vs standards. (e) CLSM 
visualization of FITC-Aβ1–42 or FITC-Trf uptake into K562 cells and SDC transfectants. Nuclei of cells were 
stained with DAPI. Representative images of three independent experiments are shown. Scale bar = 5 μm.
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attachment to SDC3 transfectants was significantly (p < 0.01) reduced (Fig. 3c,d). Microscopic visualization 
demonstrated similar results as Aβ1–42-treated SDC transfectants exhibited higher intracellular fluorescent 
signals (Fig. 3e). On SDC transfectants, significant amount of fluorescence also arose from externally bound 
FITC-Aβ1–42. Trf treated cells on the other hand, exhibited fluorescent vesicle-like intracytoplasmic structures, 
a characteristic feature of clathrin-mediated endocytosis, but lacked surface attached aggregate-like structures 
observed on Aβ1–42-treated SDC transfectants (Fig. 3e).
CLSM colocalization studies showed strong intracellular colocalization of SDCs with Aβ1–42 (the Mander’s 
overlap coefficients [MOC] between Aβ1–42 and SDCs were all greater than 0.7, referring to strong colo-
calization), suggesting the common intracellular pathway SDCs and Aβ1–42 follow during cellular entry 
(Fig. 4a,b). It is worth noting that like neurons, SH-SY5Y neuroblastoma cells endogenously express SDC3 
(Supplementary Fig. S4) and colocalization of SDC3 with Aβ1–42 could be also demonstrated in the SH-SY5Y 
cell-line (MOC = 0.81 ± 0.39; Fig. 4e,f). Co-immunoprecipitation on Aβ1–42 treated SDC transfectants and WT 
SH-SY5Y cells also confirmed that Aβ1–42 binds SDC3 (Supplementary Fig. S5). Unlike Aβ1–42, Trf did not 
exhibit colocalization with any SDCs after 18 h of incubation (MOC ≈ 0.25; Fig. 4c,d and f).
SDC-mediated uptake of Aβ1–42 occurs through membrane microdomains. It has been reported, 
that HSPGs are endocytosed through a clathrin- and caveolin-independent, but flotillin-dependent route69. The 
flotillin family of membrane proteins, namely flotillin 1 (FLOT1) and flotillin 2 (FLOT2) define specific micro-
domains in the plasma membrane. Flotillins have been long considered markers of lipid rafts because they are 
detergent insoluble and float in sucrose density gradients. CLSM studies showed the intracellular colocalization 
of both flotillins with Aβ1–42 and SDCs in SDC transfectants, while WT SH-SY5Y cells also exhibited intraneu-
ronal colocalization of flotillins with Aβ1–42 and SDC3, suggesting that SDC-dependent uptake of Aβ1–42 occur 
through lipid rafts (Fig. 5a–f). With affinity-based proteomics FLOT1 and -2 were detected in a pull-down exper-
iment of SDC4 with 43/210/79.9% and 41/203/72.7% frequency (number of unique peptide/peptide count/cov-
erage, respectively), thus confirming the findings of the CLSM colocalization studies (Supplementary Table S1).
Effect of SDC domains on Aβ1–42 uptake and fibrillation. To understand the involvement of SDC 
domains in the interaction with Aβ1–42, we set up studies where various parts of the SDC ectodomain were 
affected. First we induced undersulfation of SDCs’ HS chains with sodium chlorate (NaClO3), a well-known 
inhibitor of protein sulfation70,71. Promoting undersulfation of SDCs with NaClO3 exerted an evident and signifi-
cant (p < 0.05) inhibition of Aβ1–42 attachment in all cells lines, however the inhibitory effect on uptake was only 
significant (p < 0.05) in case of SDC3 and 4 transfectants (especially SDC3 and 4) than in WT K562 cells (Fig. 6c). 
Scanning electron microscopy studies also confirmed the inhibitory effect of undersulfation as fibrillary assem-
blies of Aβ1–42 were reduced due to NaClO3 treatment (Fig. 6d). Next we created structural mutants of SDC4, 
an isoform that exhibited high uptake efficacy of Aβ1–42 in the previous uptake assays. As SDC4 has a specific 
cell-binding-domain (CBD) that mediates cell-to-cell attachment, we also addressed the potential contribution 
of CBD to interaction with Aβ1–42. Thus a number structural mutants of SDC4 were created, including the CBD.
pSi4 made of the CBD and the secretion signal sequence (Si), but lacking any HS chains. HSA.pSi4 mutants on the 
other hand lack CBD, but contain the HS attachment site (HSA) with the HS chains, while pSi4 mutants possess a 
truncated extracellular domain made of only the Si of SDC4 (Fig. 7a). All of the above mentioned SDC4 mutants, 
along with one coding WT SDC4, were tagged with GFP at the juxtamembrane region and expressed in K562 
cells. Clones with equal extent of GFP, hence SDC expression were then selected with flow cytometry and – along 
with WT K562 cells as controls – treated with Aβ1–42 for 18 h at 37 °C. Cellular uptake and attachment was then 
analyzed with flow cytometry, as well as confocal and scanning electron microscopy. Compared to K562 cells, 
WT SDC4 transfectants exhibited the most significant (p < 0.01) increase in Aβ1–42 uptake (Fig. 7b,c). Mutants 
lacking HS chains (i.e. pSi4 or CBD.pSi4) did not induce any increase in Aβ1–42 uptake, suggesting that neither 
the signal sequence nor the CBD domain interacts significantly with Aβ1–42. Mutants with truncated ectodo-
main made of only the HSA with the HS chains on the other hand increased Aβ1–42 internalization at an extent 
similar to SDC4 transfectants, showing the paramount importance of polyanionic HS chains in the interactions 
with Aβ1–42. Similarly to SDC4 transfectants, microscopic visualization also confirmed the intracellular colocal-
ization of HSA.pSi4 with Aβ1–42 (MOC = 0.74), suggesting that Aβ1–42 enters the cells attached to HS chains 
of SDC4 (Fig. 7d,e). Scanning electron microscopy then demonstrated a less pronounced fibrillary assemblies of 
Aβ1–42 on SDC4 mutants lacking HS chains (Fig. 7e).
After assessing SDCs’ contribution to Aβ1–42 fibrillation and cellular entry in SDC overexpressing K562 cells, 
we also analyzed the contribution of SDC3 to Aβ1–42 fibrillation and uptake in the more complex SH-SY5Y 
neuronal model cell line. Thus SDC3 overexpressing SH-SY5Y cells were created and the effect of SDC3 overex-
pression on Aβ1–42 fibrillation and uptake cellular was studied. In SH-SY5Y cells, SDC3 overexpression resulted 
in increased HS expression, along with increased cellular uptake and fibrillation of Aβ1–42 (Fig. 8a–e). Thus a 
very definite correlation was found between SDC3 overexpression and Aβ1–42 uptake (r = 0.63) or fibrillation 
(r = 0.80) in SH-SY5Y neurons (Fig. 8c,d). HS expression also exhibited high correlation with Aβ1–42 uptake 
(r = 0.74) and fibrillation (r = 0.79), further confirming the roles of HS chains in interactions with Aβ1–42 
(Fig. 8c,d).
Discussion
There is compelling evidence that Aβ1–42, rendered in β-sheet dominated senile plaques, is a hallmark of 
Alzheimer’s disease (AD) in the brain of late-life dementia patients. Despite of growing criticism on the Aβ 
hypothesis, new lines of evidence support the concept that an imbalance between production and clearance of 
Aβ1–42 peptides is a very early, often initiating factor in Alzheimer’s disease (AD)72. Intraneuronal accumulation 
of Aβ aggregates due to Aβ re-uptake has been observed to precede extracellular plaque formation in AD18,19,73,74. 
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As detailed exploration of Aβ1–42 endocytosis contributes to the understanding of cellular pathomechanism of 
neurodegeneration, extensive studies have been conducted and revealed the macropinocytic nature of Aβ1–42 
cellular uptake and the involvement of cell surface HSPGs13,67,75–77. Meanwhile, our research group has been 
Figure 4. Colocalization of Aβ1–42 and SDCs. SDC transfectants or WT SH-SY5Y cells were treated with 
either FITC-Aβ1–42 or FITC-Trf for 18 h at 37 °C. After incubation, the cells were permeabilized and treated 
with the respective APC-labeled SDC antibody. Nuclei of cells were stained with DAPI and cellular uptake was 
then analyzed with CLSM. (a,c) CLSM images of SDC transfectants treated either FITC-Aβ1–42 (a) or FITC-
Trf (c) and respective APC-labeled SDC antibody. Representative images of three independent experiments 
are shown. Scale bar = 5 μm. (b,d) Mander’s overlap coefficient (MOC) ± SEM for the overlap of SDCs with 
FITC-Aβ1–42 (b) or FITC-Trf (d) was calculated by analysis of 21 images with ~7 cells in each image (from 
three separate samples). (e) CLSM images of WT SH-SY5Y cells treated with FITC-Aβ1–42 or FITC-Trf, along 
with APC-labeled SDC3 antibody. Representative images of three independent experiments are shown. Scale 
bar = 10 μm. (f) Mander’s overlap coefficient (MOC) ± SEM for the overlap of SDC3 with FITC-Aβ1–42 or 
FITC-Trf was calculated by analysis of 21 images with ~7 cells in each image (from three separate samples)
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Figure 5. Colocalization of SDCs, Aβ1–42 and flotillins. SDC transfectants and WT SH-SY5Y cells were treated 
with 5-TAMRA-labeled Aβ1–42 for 18 h at 37 °C. After incubation, the cells were permeabilized and treated 
with the respective APC-labeled SDC antibody, along with either flotillin 1 (FLOT1) or flotillin 2 (FLOT2) 
antibodies (both Alexa Fluor 488-labeled). Nuclei of cells were stained with DAPI and cellular uptake was 
then analyzed with CLSM. Representative images of three independent experiments are shown. (a,c) CLSM 
images of SDC transfectants treated with FITC-Aβ1–42, one of the anti-flotillin antibodies and a respective 
APC-labeled SDC antibody. (b,d) Mander’s overlap coefficient (MOC) ± SEM for the overlap of SDCs with 
either FLOT1 or FLOT2 was calculated by analysis of 21 images with ~7 cells in each image (from three separate 
samples). (e) CLSM images of WT SH-SY5Y cells treated with 5-TAMRA-labeled Aβ1–42, APC-labeled SDC3 
antibody and FLOT1 or FLOT2 antibodies. Scale bar = 10 μm. (f) Mander’s overlap coefficient (MOC) ± SEM 
for the overlap of SDC3 with either FLOT1 or FLOT2 was calculated by analysis of 21 images with ~7 cells in 
each image (from three separate samples).
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Figure 6. Effect of undersulfation on Aß1–42 uptake and binding. WT K562 cells and SDC transfectants were 
incubated with sodium chlorate (NaClO3) prior to Aβ1–42 treatment. Effect of NaClO3 on HS expression, 
along with Aβ1–42 and attachment were assessed with flow cytometry. (a) Flow cytometry histograms showing 
HS expression of WT K562 cells or SDC transfectants after NaClO3 treatment. (b) Flow cytometry histograms 
representing intracellular fluorescence of FITC-Aβ1–42-treated cells preincubated with or without NaClO3. 
(c) The effect of NaClO3 were expressed as percent inhibition, calculated with the following formula: [(X − 
Y)/X] × 100, where X is the fluorescence intensity obtained on cells treated with Aβ1–42 in the absence of the 
NaClO3 and Y is the fluorescence intensity obtained on cells treated with either Aβ1–42 in the presence of the 
NaClO3. The bars represent mean ± SEM of four independent experiments. Statistical significance vs controls 
untreated with NaClO3 was assessed by analysis of variance (ANOVA). *p < 0.05 vs standards; **p < 0.01 
vs standards; ***p < 0.001 vs standards. (d) Scanning electron microscope visualization of cellular surface 
of Aβ1–42-treated WT K562 cells and SDC3, SDC4 transfectants, preincubated with or without NaClO3. 
Representative images of three independent experiments are shown. Scale bar = 1 μm.
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Figure 7. Contribution of various parts of the SDC4 ectodomain to Aβ1–42 uptake. WT K562 cells and 
SDC4 mutants were treated with Aβ1–42 at a concentration of 5 μM at 37 °C. (a) Schematic representation 
of SDC4 deletion mutants used in the study. (b) Flow cytometry histograms representing HS expression and 
intracellular fluorescence of WT K562 cells and SDC4 mutants treated with FITC-Aβ1–42 for 18 h. (c) Results 
of flow cytometric measurements. Detected fluorescence intensities are normalized to FITC-Aβ1–42-treated 
WT K562 cells as standards. The bars represent mean ± SEM of four independent experiments. Statistical 
significance vs FITC-Aβ1–42-treated WT K562 cells was assessed by analysis of variance (ANOVA). **p < 0.01 
vs standards; ***p < 0.001 vs standards. (d) CLSM visualization of SDC4 or HSA.pSi4 transfectants treated with 
FITC-Aβ1–42 for 18 h. Scale bar = 5 μm. (e) Mander’s overlap coefficient (MOC) ± SEM for the overlap of Aβ1–
42 with either SDC4 or HAS.pSi4 was calculated by analysis of 21 images with ~7 cells in each image (from three 
separate samples). (f) Scanning electron microscope visualization of cellular surface of Aβ1–42-treated WT K562 
cells and SDC4 mutants. Representative images of three independent experiments are shown. Scale bar = 1 μm.
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Figure 8. Effect of SDC3 on Aβ1–42 uptake and fibrillation in neurons. SDC3 transfectants created in SH-SY5Y 
cells were selected by measuring SDC3 expression with flow cytometry using APC-labeled anti-SDC3 antibody. HS 
expression of SDC3 transfectants, along with WT SH-SY5Y, was also measured with flow cytometry using anti-HS 
antibody. SDC3 transfectants and WT SH-SY5Y cells were treated with Aβ1–42 (with or without FITC label) at a 
concentration of 5 μM at 37 °C. Cells incubated with Aβ1–42 for 18 h were then processed for uptake, fibrillation 
studies and scanning electron microscopy. (a) Flow cytometry histograms representing SDC3, HS expression 
levels and intracellular fluorescence of Aβ1–42-treated WT SH-SY5Y cells and SDC3 transfectants. (b) Fold 
change in SDC3 and HS expression, along with Aβ1–42 uptake and fibrillation following SDC3 overexpression. 
The bars represent mean ± SEM of six independent experiments. Statistical significance vs Aβ1–42-treated WT 
SH-SY5Y cells (standards) was assessed by analysis of variance (ANOVA). *p < 0.05 vs Aβ1–42-treated WT SH-
SY5Y cells (standards). (c,d) Linear regression between HS or SDC3 expression and Aβ1–42 uptake or fibrillation. 
(e) Scanning electron microscopy visualization of Aβ1–42 attachment and fibrillation on WT SH-SY5Y cells and 
SDC3 mutants. Representative images of three independent experiments are shown. Scale bar = 2 μm.
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exploiting the SDC-mediated macropinocytic delivery of peptides that enables the efficient intracellular trans-
port of bioactive macromolecules56,58. Considering the similarities on the cellular uptake of CPPs and Aβ1–42, 
we investigated the cellular uptake of Aβ1–42 in cellular models specific to various SDC isoforms. Our stud-
ies explored the exact contribution of each SDC isoform to Aβ1–42 internalization: overexpression of all SDCs 
increased the uptake of Aβ1–42, however the increase was fairly different among the various SDC isoforms. 
Thus the neuron specific SDC3 increased Aβ1–42 uptake from the earliest time points and SDC4, the univer-
sally expressed isoform of the family, increased Aβ1–42 uptake at a pace similar to SDC3. Contrary to SDC3 
and 4, SDC1- and 2-mediated internalization of Aβ1–42 was markedly slower. SDC-mediated cellular entry of 
Aβ1–42 via SDCs was shown to occur through lipid rafts and attachment to polyanionic HS chains. Among the 
various parts of the SDC ectodomain, the HS chains proved to have a major role in interacting with Aβ1–42. As 
SDC transfectants applied expressed equal amount of HS, the observed difference between the various SDCs in 
Aβ1–42 fibrillation could be attributed to the structural differences in HS chains of the distinct SDC isoforms. 
Also the different SDC isoforms interact with different set of intracellular signaling molecules and that could also 
contribute to the observed difference in Aβ1–42 uptake.
The high affinity of Aβ1–42 towards the neuron specific SDC3 isoform, along with the fast and marked uptake 
into SDC3 transfectants, could account for the tendency of Aβ1–42 affecting neurons: SDC3 on neurons would 
bind and internalize Aβ1–42 even before it could be cleared off the extracellular space by phagocytic cells. The 
observation SDC3 overexpression triggers Aβ1–42 fibrillation suggest that significant part of Aβ1–42 enter 
SDC3 expressing cells in fibrillar form, thus implying the negative effect of SDC3 overexpression on neurons, as 
observed by Liu et al. in their present study on postmortem human AD brains11. The decreased uptake of Trf, the 
marker of clathrin-dependent endocytosis, into SDC3 transfectants also implies that SDC3 overexpression affects 
the classical endocytosis, thus clearance of Aβ1–42, leading to intraneuronal accumulation of oligomeric Aβ1–42 
via lipid-raft dependent, alternative endocytic pathways.
Overall, our data represents SDCs, especially SDC3 and SDC4 as a preferred cellular targets for Aβ1–42 to 
enter the cells. Considering significant overexpression of SDC3 and SDC4 in human AD brains, our SDC depend-
ent cellular assays provided results relevant to human conditions and revealed unknown details of SDC-mediated 
endocytosis and fibrillation of Aβ1–42. The observation that SDC3 overexpression, regardless of cell type, can 
contribute to fundamental biological processes (i.e. uptake and fibrillation) related to Aβ1–42 pathology, high-
lights SDCs, especially SDC3, the neuron specific member of the SDC family with increased expression in AD 
brains as important players in the pathophysiologic events of neurodegeneration.
Methods
Peptides. Fluorescently labeled (FITC, 5-TAMRA and HiLyte™ Fluor 647) Aβ1–42 was purchased from 
BACHEM and AnaSpec, respectively. FITC-labeled human Trf, the marker of clathrin-mediated endocytosis was 
purchased from Thermo Fisher Scientific.
SDC constructs, cell culture and transfection. Full-length SDC1-4 and SDC4 deletion mutants were 
amplified and subcloned in the mammalian expression plasmid obtained from Clontech (pcDNA3, pEGFP). 
Structural SDC4 mutants were constructed by inserting green fluorescent protein (GFP) into the juxtamembrane 
region of the extracellular segment. The signals were kept in all cases to orient the proteins into the membrane. 
Human SDC DNA constructs were prepared as described above and transfected into K562 cells with DMRIE-C 
(Invitrogen) to establish stable cell lines permanently expressing human SDCs or SDC4 structural mutants56. 
Transfections were carried out according to the recommendations of the manufacturer. After 24 h, cells were 
incubated with selection medium, containing 0.4 mg/ml G418 (Sigma). Selection medium was changed every 
second day. After 2 weeks, G418-resistant colonies were analyzed for the SDC expression with flow cytometry 
using APC-labeled antibodies specific for the given SDC isoforms (R&D Systems). In case of GFP-tagged SDC4 
mutants, expression was analyzed with flow cytometry measuring fluorescence intensities of the GFP tags. Thus 
colonies exhibiting marked SDC expression were chosen for further studies. The erythroleukemia cell line K562 
and its SDC clones were grown as a suspension culture in DMEM/F12 medium (Thermo Fischer Scientific) sup-
plemented with 10% fetal calf serum (FCS; Gibco) at 37 °C in a humified 5% CO2 containing air environment. 
In case of SDC3 overexpressing SH-SY5Y cells, transfection and selection of SDC3 overexpressing clones were 
carried out as described above. SDC3 overexpressing SH-SY5Y clones, along with WT SH-SY5Y cells were then 
grown in Advanced MEM medium (Thermo Fischer Scientific) supplemented with 10% FCS (Gibco) at 37 °C in 
a humified 5% CO2 containing air environment.
Flow cytometry analysis of HS and CS expression. As HS was shown to attach Aβ1–42, HS expression 
of wild-type (WT) K562 cells, SDC transfectants and SH-SY5Y cells were measured with flow cytometry by using 
anti-human HS antibody (10E4 epitope [Amsbio]) and FITC- or Alexa 647-labeled goat anti-mouse IgG (Sigma) 
according to the manufacturers’ protocols. SDC transfectants with almost equal amount of HS expression were 
selected for further uptake studies. SDC transfectants were also assessed for CS expression, using monoclonal 
anti-CS primary antibody (Clone CS-56, Sigma) and FITC-labeled goat anti-mouse IgG (Sigma) according to the 
manufacturers’ protocols.
Flow cytometry analysis of cellular uptake. WT K562 and SH-SY5Y cells, SDC transfectants, along 
with SDC4 structural mutants were utilized to quantify internalization of fluorescently labeled Aβ1–42 or Trf. 
Briefly, 6 × 105 cells/ml in DMEM/F12 medium (with 10% FCS) were incubated with fluorescently labeled 
(FITC-, or in the case of SDC4 mutants, HiLyte™ Fluor 647) Aβ1–42 or Trf (at a concentration of 5 μM and 25 μg/
ml, respectively), for various amounts of time (1, 3, 6 and 18 h) at 37 °C. After incubation the cells were washed 
twice in ice cold PBS and progressed towards flow cytometry. In the case of the FITC-Aβ1–42 and Trf-treated 
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cells, after incubation and washing, the cells (WT K562, SH-SY5Y and SDC transfectants) were resuspended 
in 0.5 ml of physiological saline. Equal volumes of this suspension and a stock solution of trypan blue (Merck 
KGaA; 500 μg/ml dissolved in ice-cold 0.1 M citrate buffer at pH 4.0) were allowed to mix for 1 min before the 
flow cytometric analyses. In this way, sample pH was lowered to pH 4.0, thereby optimizing the quenching effect 
of trypan blue to quench the extracellular fluorescence of surface bound fluorescent proteins66. In the case of the 
SDC4 mutants treated with HiLyte™ Fluor 647-labeled Aβ1–42, extracellular fluorescence of surface attached 
peptides was removed by trypsinization according to the method described by Nakase et al.78. Cellular uptake 
and attachment was then measured by flow cytometry using a FACScan (Becton Dickinson). Cellular attachment 
was calculated by subtracting intracellular fluorescence (i.e. those quenched with trypan blue or trypsin) from 
measures of overall fluorescence. A minimum of 10,000 events per sample was analyzed. Viability of cells was 
determined by appropriate gating in a forward-scatter-against-side-scatter plot to exclude dead cells and debris.
Microscopic visualization of cellular uptake. Internalization of the fluorescently labeled (either 
FITC, 5-TAMRA or HiLyte™ Fluor 647) Aβ1–42 or Trf was visualized by confocal laser scanning microscopy 
(CLSM). WT SH-SY5Y and WT K562 cells, along with SDC transfectants and SDC4 mutants were grown on 
poly-D-lysine-coated glass-bottom 35-mm culture dishes (MatTek Corp.). After 24 h, the cells were preincubated 
in DMEM/F12 medium (Supplemented with 10% FCS) at 37 °C for 30 min before incubation with the fluores-
cently labeled Aβ1–42 or Trf at a concentration of 5 μM and 25 μg/ml, respectively. After incubation, the cells were 
rinsed two times with ice-cold PBS, fixed in 4% paraformaldehyde (Sigma) and nuclei were stained with DAPI 
(1:5000, Sigma) for 5 min. For colocalization studies, after fixation, the cell membranes were permeabilized (1% 
Triton X-100), followed by 1 h of treatment with APC-labeled SDC antibodies (1:100) with or without either of 
the Alexa Fluor® 488-labeled flotillin antibodies (flotillin-1 or 2, all Santa Cruz Biotech). The samples were then 
rinsed three times with PBS containing 1% goat serum and 0.1% Triton X-100, then stained with DAPI (1:5000) 
for 5 min, washed three times with PBS and embedded in Fluoromount G (SouthernBiotech). Distribution of 
fluorescence was then analyzed on an Olympus FV1000 confocal laser scanning microscope equipped with three 
lasers. A laser diode (excitation, 405 nm) and a band-pass filter (420–480 nm) were used to capture the signal 
recorded as blue; an argon laser (excitation, 488 nm) and a bandpass filter (505–530 nm) were used to capture the 
signal recorded as green; and finally, a helium/neon laser (excitation, 543 nm) and a band-pass filter (550–625 nm) 
were used to capture the signal recorded as red. Sections presented were taken approximately at the mid-height 
level of the cells. Photomultiplier gain and laser power were identical within each experiments. FV10-ASW 
software was used for image acquisition by confocal microscopy. For visualizing internalization of oligomeric 
Aβ1–42, WT K562 cells and SDC transfectants grown on poly-D-lysine-coated glass-bottom 35-mm culture 
dishes were incubated with Aβ1–42 (BACHEM) at a concentration of 5 µM (in DMEM/F-12 without Phenol 
Red) at 37 °C for 18 h, then treated with Thioflavin T (ThT, Sigma) at a concentration of 25 µM for 10 min at 37 °C 
and rinsed two times with ice-cold PBS. After fixation in 4% paraformaldehyde (Sigma), nuclei were stained with 
DAPI (1:5000) for 5 min, the after three washing with PBS, the samples were embedded in Fluoromount G and 
distribution of fluorescence was analyzed on an Olympus FV1000 confocal laser scanning as described above. 
For colocalisation analyses (SDCs with Aβ1–42 or Trf; SDCs with flotillins, SDC3 with Aβ1–42 or flotillins) 
the images were analyzed in the ImageJ software (NIH, Bethesda, Maryland, US) with the plug-in JACoP28 as 
described by Wesén et al.13 21 images (7 images per sample, experiment performed in triplicate) were analysed, 
and the data is presented as mean ± SEM.
Co-immunoprecipitation experiments. Stable SDC3 transfectants or WT SH-SY5Y cells were incubated 
with or without FITC-labeled Aβ1–42 at a concentration for 18 h at 37 °C. After incubation the cells were washed 
twice with ice cold PBS and treated with cold Pierce IP lysis buffer. Then the cells were scrapped off to clean 
Eppendorf tubes, put on a low-speed rotating shaker for 15 min and centrifuged at 14,000 g for 15 min at 4 °C. 
The supernatant were then transferred to new tubes and combined with 5 µg of the human SDC3 antibody (R&D 
Systems). The antigen sample/SDC3 antibody mixture was then incubated for overnight at 4 °C with mixing. The 
antigen sample/SDC3 antibody mixture then were added to a 1,5 ml microcentrifuge tube containing pre-washed 
Pierce Protein A/G Magnetic Beads (Thermo Fisher Scientific) and after incubation at room temperature for 
1 hour with mixing, the beads were then collected with a MagJET Separation Rack magnetic stand (Thermo 
Fisher Scientific) and supernatants were discarded. To eluate the antigen, 100 µl of SDS-PAGE reducing sample 
buffer were then added to the tubes and samples were heated at 96 °C for 10 minutes and the samples were pro-
ceeded to SDS-PAGE.
Affinity-based proteomics of SDC4 interactions. To reveal the SDC4 protein interactome, whole cell 
extracts were prepared from stable transfectant of GFP-tagged SDC4, and then a GFP co-immunoprecipitation 
(GFP co-IP) assay was performed. Protein concentration of the whole cell extract (WCE) was determined by 
using Bradford Protein Assay (Bio-Rad, Hercules, California, USA), according to the manufacturer’s instruc-
tions. Total protein extracts (2 mg) were immunopurified (IP) using 40 µl anti-GFP antibody-coupled 50 nm 
superparamagnetic beads (µMACS GFP Isolation Kit, Miltenyi Biotec, Germany). The unbound material was 
removed by washing the beads with 2 ml (equal to 50x beads volume) detergent-free buffers as follows: three 
times with 1x TBS and once with 25 mM ABC(NH4HCO3) buffer. The immunopurified proteins were desalted 
after on-bead-digestion with trypsin (Promega, Germany)79. The LC-MS/MS analysis was performed by using 
a nanoflow RP-HPLC on-line coupled to a linear ion trap-Orbitrap (Orbitrap-Elite, Thermo Fisher Scientific, 
Germany) mass spectrometer as in a previous study with the following modification: the 20 most abundant, 
multiply charged ions were selected from each MS survey for MS/MS analysis80. Raw data were converted into 
peak lists using Proteome Discoverer (v 1.4, Thermo Fisher Scientific). First, we performed a search against the 
Swissprot and Uniprot databases, taking into consideration of the sequence of SDC4. Search parameters and 
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acceptance criteria were set as previously published. Close homologues were only reported if at least three unique 
peptides matched to the protein. Spectral counting was used to estimate relative abundance of individual pro-
teins in the samples: peptide counts of the individual proteins were normalized to the total number of peptide 
identifications in each sample81. Proteins (i) with reproducible detection (|log 2 fold-change| <0.67 between 
biological replicates), (ii) with at least two identified peptides, (iii) with at least 5% coverage and (iv) with a 
median-normalized protein binding affinity score above a previously defined cut-off value were considered as 
proteins that specifically associate with SDC482.
Thioflavin T binding assays. WT K562, SH-SY5Y cells and SDC transfectants seeded into black-sided, 
clear bottom 96-well microplates (Corning) at a density of 1,5 × 105 cells/well in 100 µl of DMEM/F-12 (without 
Phenol Red) were exposed to Aβ1–42 at a concentration of 5 µM for various amounts of time (1, 3, 6 and 18 h) at 
37 °C. After the incubation periods, Thioflavin T (ThT) was added to the Aβ1–42-treated cells at a concentration 
of 15 µM and after 10 min of incubation fluorescence was measured with Cytation™ 3 Multi-Mode reader (BioTek 
Instruments) using an excitation wavelength of 440 nm and an emission of 480 nm. Photomultiplier gain was 
set at 50. Fluorescence measurements are made from the bottom of the plate, with the top being sealed with an 
adhesive plate sealer to prevent evaporation. The fold change in ThT fluorescence intensity over background ThT 
signal was calculated by dividing the fluorescence intensity of the Aβ1–42-treated cells incubated with ThT by the 
respective fluorescence intensity of the ThT-incubated (same) cell line untreated with Aβ1–4283.
Scanning electron microscopy of surface attachment and fibrillation of Aβ1–42. WT SH-SY5Y 
and WT K562 cells, along with SDC transfectants and SDC4 mutants were grown on poly-D-lysine-coated 
glass-bottom 35-mm culture dishes. After 24 h, the cells were preincubated in DMEM/F12 medium (supple-
mented with 10% FCS) at 37 °C for 30 min before incubation with Aβ1–42 at a concentration of 5 μM for 1, 6 or 
18 h. Then the cells were rinsed two times with ice-cold PBS, then fixed in 2.5% glutaraldehyde and 0.15% alcian 
blue 8GX (Sigma) for 1 hour. After post-fixation in 1% OsO4 (Sigma) for 1 hour the samples were dehydrated 
in aqueous solutions of increasing ethanol concentrations, critical point dried, covered with 10 nm gold by a 
Quorum Q150T ES sputter and observed in a JEOL JSM-7100F/LV scanning electron microscope.
Promoting undersulfation. To study the effect of proteoglycan sulfation, cells were incubated with 60 mM 
sodium chlorate (NaClO3; Sigma) for 48 h, the processed for the flow cytometry and microscopy studies as 
described above.
Statistical analysis. Results are expressed as means ± standard error of the mean (SEM). Differences 
between experimental groups were evaluated by using one-way analysis of variance (ANOVA). Values of p < 0.05 
were accepted as significant. Pearson’s correlation coefficient was calculated for correlation between the SDC3 
or HS expression and Aβ1–42 uptake and fibrillation values of SH-SY5Y cells. For colocalisation analyses, the 
Mander’s overlap coefficient (MOC) was calculated as described by Wesen et al.13.
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